applied molecular transport is developing a pipeline of transformative, targeted oral biological therapeutics that promise to redefine the future of biopharmaceuticals. our deep scientific foundations in mucosal immunology and microbiome-epithelial interfaces have led to the development of powerful technology platforms that are fueling a unique pipeline of first-in-class molecules to treat a wide range of grievous diseases. our oral biopharmaceutical products mimic the biology of microbial and other natural processes that modulate health and disease via mucosal immunology pathways. our targeted therapeutics are directed to the right location to intercept disease at the point of origin of dysregulation. we are advancing a pipeline of targeted oral biological therapeutics to treat autoimmune, inflammation and other diseases, including those associated with cancer, metabolic and hepatologic disorders. our overriding patient-centric goal is to open new biological possibilities based on nov